EU at Crossroads: Balancing Innovation and Access in Pharmaceutical Sector

Europe faces a critical moment in maintaining access to new drugs amid U.S. pricing policies. The European Medicines Agency's Emer Cooke highlights a significant drop in drug launches, urging for collaborative regional efforts. The impact of U.S. policies poses challenges on clinical trials, pricing, and market launches.

Emer Cooke, head of the European Medicines Agency, warns that Europe is at a pivotal stage in securing access to new medications, as U.S. pricing policies create ripples across the sector. Speaking at the Reuters Pharma Europe 2026 event, Cooke highlighted a troubling decrease in drug launches, raising concerns over patient access to innovative treatments.

The U.S. drug pricing initiative has led companies to reconsider the benefits of launching in Europe, with some delaying introductions or pushing for higher prices. Bill Coyle of ZS adds that the 'most-favored-nation' policy links U.S. prices to those in wealthier countries, prompting hesitation among drugmakers.

Despite industry criticism, Cooke defends Europe's role as a major pharmaceuticals market with its universal healthcare system. She emphasizes efforts to reform regulatory frameworks and improve competitiveness within the EU, aiming to retain scientific talent and spur innovation.